324 related articles for article (PubMed ID: 16628588)
1. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial.
Ide F; Nakamura T; Tomizawa M; Kawana-Tachikawa A; Odawara T; Hosoya N; Iwamoto A
J Med Virol; 2006 Jun; 78(6):711-8. PubMed ID: 16628588
[TBL] [Abstract][Full Text] [Related]
2. Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.
Cobb A; Roberts LK; Palucka AK; Mead H; Montes M; Ranganathan R; Burkeholder S; Finholt JP; Blankenship D; King B; Sloan L; Harrod AC; Lévy Y; Banchereau J
J Immunol Methods; 2011 Feb; 365(1-2):27-37. PubMed ID: 21093448
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy.
Zhang Z; Zhao QX; Fu JL; Yao JX; He Y; Jin L; Wang FS
Chin Med J (Engl); 2006 Dec; 119(23):1949-57. PubMed ID: 17199938
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell vaccination induces cross-reactive cytotoxic T lymphocytes specific for wild-type and natural variant human immunodeficiency virus type 1 epitopes in HLA-A*0201/Kb transgenic mice.
Abdel-Motal UM; Friedline R; Poligone B; Pogue-Caley RR; Frelinger JA; Tisch R
Clin Immunol; 2001 Oct; 101(1):51-8. PubMed ID: 11580226
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection.
García F; Lejeune M; Climent N; Gil C; Alcamí J; Morente V; Alós L; Ruiz A; Setoain J; Fumero E; Castro P; López A; Cruceta A; Piera C; Florence E; Pereira A; Libois A; González N; Guilá M; Caballero M; Lomeña F; Joseph J; Miró JM; Pumarola T; Plana M; Gatell JM; Gallart T
J Infect Dis; 2005 May; 191(10):1680-5. PubMed ID: 15838795
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption.
Harrer E; Bäuerle M; Ferstl B; Chaplin P; Petzold B; Mateo L; Handley A; Tzatzaris M; Vollmar J; Bergmann S; Rittmaier M; Eismann K; Müller S; Kalden JR; Spriewald B; Willbold D; Harrer T
Antivir Ther; 2005; 10(2):285-300. PubMed ID: 15865223
[TBL] [Abstract][Full Text] [Related]
7. Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment.
Calarota SA; Leandersson AC; Bratt G; Hinkula J; Klinman DM; Weinhold KJ; Sandström E; Wahren B
J Immunol; 1999 Aug; 163(4):2330-8. PubMed ID: 10438897
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characteristics of HIV-specific CD8 T cells and gag sequence variability after autologous dendritic cells based therapeutic vaccine.
López A; van der Lubbe N; Sánchez-Palomino S; Arnedo M; Nomdedeu M; Castro P; Guilà M; Maleno MJ; García F; Gallart T; Gatell JM; Plana M
Vaccine; 2009 Oct; 27(44):6166-78. PubMed ID: 19712765
[TBL] [Abstract][Full Text] [Related]
9. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.
Kloverpris H; Karlsson I; Bonde J; Thorn M; Vinner L; Pedersen AE; Hentze JL; Andresen BS; Svane IM; Gerstoft J; Kronborg G; Fomsgaard A
AIDS; 2009 Jul; 23(11):1329-40. PubMed ID: 19528789
[TBL] [Abstract][Full Text] [Related]
10. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
Andrieu JM; Lu W
J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
[TBL] [Abstract][Full Text] [Related]
11. Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV).
Boström AC; Hejdeman B; Matsuda R; Fredriksson M; Fredriksson EL; Bratt G; Sandström E; Wahren B
Vaccine; 2004 Apr; 22(13-14):1683-91. PubMed ID: 15068851
[TBL] [Abstract][Full Text] [Related]
12. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
13. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
[TBL] [Abstract][Full Text] [Related]
14. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
[TBL] [Abstract][Full Text] [Related]
15. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
[TBL] [Abstract][Full Text] [Related]
16. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
Lu W; Arraes LC; Ferreira WT; Andrieu JM
Nat Med; 2004 Dec; 10(12):1359-65. PubMed ID: 15568033
[TBL] [Abstract][Full Text] [Related]
19. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
Isgrò A; Leti W; De Santis W; Marziali M; Esposito A; Fimiani C; Luzi G; Pinti M; Cossarizza A; Aiuti F; Mezzaroma I
Clin Infect Dis; 2008 Jun; 46(12):1902-10. PubMed ID: 18462177
[TBL] [Abstract][Full Text] [Related]
20. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
